منابع مشابه
Trial Validates Biosimilar for Trastuzumab.
Preliminary data from the phase III Heritage trial suggest that a biosimilar to trastuzumab, MYL-14010, is just as safe and effective as its brand-name equivalent for women with HER2-positive advanced breast cancer. The findings, presented during the annual meeting of the American Society of Clinical Oncology in June, may pave the way for the first FDA-approved biosimilar for cancer.
متن کاملPhysicochemical and Biological Characterization of a Biosimilar Trastuzumab
According to the World Health Organization, the incidence of malignant neoplasms and endocrine, blood, and immune disorders will increase in the upcoming decades along with the demand of affordable treatments. In response to this need, the development of biosimilar drugs is increasing worldwide. The approval of biosimilars relies on the compliance with international guidelines, starting with th...
متن کاملOptimization of HER2-based and cell-based ELISA for detection of trastuzumab biosimilar
Introduction: ELISA is a sensitive, specific, reproducible and fast method to quantify the biological activity of antibodies. Trastuzumab is a humanized monoclonal antibody against HER2 receptors which prevents the initiation of downstream signaling pathway. Trastuzumab can be used as a positive control in the ELISA experiments for anti-HER2 antibodies. Additionaly, insufficient washing and blo...
متن کامل.NET Is Coming
A nnounced in July 2000, .NET, Microsoft's platform for XML-based Web services, is currently undergoing a succession of beta versions for a projected release late this year or early in 2002. .NET has a central role in Micro-soft's strategy to integrate the Internet, Web services, building block services, numerous tools for developers, and many other features. Curiously though, this next generat...
متن کاملDrifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
A biosimilar product needs to demonstrate biosimilarity to the originator reference product, and the quality profile of the latter should be monitored throughout the period of the biosimilar's development to match the quality attributes of the 2 products that relate to efficacy and safety. For the development of a biosimilar version of trastuzumab, the reference product, Herceptin®, was extensi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Tumor Medicine & Prevention
سال: 2017
ISSN: 2575-890X
DOI: 10.19080/jtmp.2017.01.555560